Beta-sitosterol vs saw palmetto: how the evidence compares
One of these has consistent trial support for urinary symptoms. The other outsells it several times over. They are not the same one — and no study has ever compared them head to head.
The short answer
- Beta-sitosterol has the more consistent trial support: a Cochrane review of four randomized trials in 519 men found better symptom scores and urine flow than placebo.
- Saw palmetto failed the two largest US trials ever run on it, including one that tripled the dose.
- No study has ever compared them directly. This is an indirect comparison, which is weaker than it sounds.
- Neither reduces prostate size. The improvement, where it exists, is in symptoms and flow.
- The practical consequence: check whether the beta-sitosterol in your formula reaches 60 mg, rather than sitting behind saw palmetto as a trace ingredient.
Pick up almost any prostate formula in an American pharmacy and both of these will be on the label. Saw palmetto will be listed first, in the largest amount, and it will be what the front of the box talks about. Beta-sitosterol will be further down, often in an amount that would not have qualified anyone for the studies it appears in.
Based on the trial evidence, that ordering is backwards.
Side by side
Ingredient Reference
Beta-sitosterol vs saw palmetto · doses from published trials
| Ingredient | Doses used in studies | What the research actually shows |
|---|---|---|
| Beta-sitosterol | 60–130 mg/day | A Cochrane review pooling four randomized trials in 519 men found improvement in urinary symptom scores and peak urine flow versus placebo. The trials were short — a few weeks to six months — and showed no change in prostate size. |
| Saw palmetto | 320 mg/day | Two large NIH-funded US trials, STEP and CAMUS, found no difference from placebo. CAMUS tested up to 960 mg/day and still found nothing. The Cochrane review reached the same conclusion. |
What beta-sitosterol actually did in the studies
Beta-sitosterol is a sterol found in most plants — it's structurally similar to cholesterol, which is roughly why the body notices it. The supplements are usually derived from pine, soy or sugarcane.
The Cochrane review that anchors its reputation pooled four randomized, placebo-controlled trials covering 519 men. Both of the outcomes that matter to a person living with this improved: the standardized urinary symptom score and the peak rate of urine flow. That is a more coherent result than saw palmetto has ever produced in a comparable review.
The caveats are real and we won't bury them. The trials were short — none ran the full year that STEP did. They were small by the standards of the saw palmetto trials that came later. They date from the 1990s, and there has been little high-quality work since to confirm or overturn them. And prostate volume did not change, meaning whatever is happening is not a reduction in the obstruction itself.
The comparison nobody has run
Here is the honest limit of this article: no researcher has put these two head to head in the same trial with the same patients.
Everything above compares each ingredient to placebo, in separate studies, run in different decades, with different populations and different criteria for entry. Indirect comparison like this is genuinely useful — it is often all the evidence there is — but it can be thrown off by differences that have nothing to do with the ingredients. Trials run in the 1990s enrolled people differently than trials run in 2011.
So the correct summary is not "beta-sitosterol beats saw palmetto." It is: beta-sitosterol has positive short-term evidence, saw palmetto has null long-term evidence, and nobody has tested them against each other.
What to do with this at the shelf
Turn the bottle over and find the beta-sitosterol line. Three outcomes:
- 60 mg or more, listed with a specific number — that is in the range the trials used.
- Present, but well under 60 mg — decorative. It's on the label so the label looks fuller.
- Inside a "proprietary blend" with one combined total — you cannot know what you're getting. That formatting is legal and it is almost always concealing underdosed ingredients.
The rest of the panel is worth reading too — particularly the zinc line, where more is actively worse.
Read the full five-ingredient breakdown →
Or the detail on why saw palmetto failed its trials →
And nettle root, which sits between the two on evidence →
Common questions
Has anyone compared the two directly?
No. There is no head-to-head randomized trial of beta-sitosterol against saw palmetto. Everything here is an indirect comparison — each against placebo, in different studies, with different patients and different measuring points. That is weaker evidence than a direct comparison and should be read as such.
Should I take both?
Most formulas already contain both, so in practice many people do. There is no trial of the combination, so nobody can tell you whether it works better than beta-sitosterol alone. What you can check is whether the beta-sitosterol in your bottle reaches the amounts used in the studies, rather than appearing as a trace behind the headline ingredient.
Is beta-sitosterol the same as a plant sterol supplement for cholesterol?
Related but not identical in dose. The plant sterol products marketed for cholesterol are typically taken at around two grams a day, far above the amounts used in the urinary symptom trials. Do not assume one substitutes for the other, and do not scale the dose up on your own reasoning.
Will either of them shrink my prostate?
Neither has been shown to. Where researchers found improvement, it was in symptom scores and flow rate, not in gland volume. Prescription 5-alpha-reductase inhibitors are the drugs that reduce prostate size, and they require a doctor.
Continue reading
Sources
- Wilt T, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews.
- Bent S, et al. Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine, 2006.
- Barry MJ, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms (CAMUS). JAMA, 2011.
- National Institute of Diabetes and Digestive and Kidney Diseases. Prostate Enlargement (Benign Prostatic Hyperplasia).